Recently, Shanghai MicroPort EP MedTech Co., Ltd. (referred to as MicroPort EP) has partnered with Stereotaxis in the 21st China Atrial Fibrillation Symposium (CAFS2023) and demonstrated the new functions of endovascular interventional robotic Magnetic Navigation System (referred to as Magnetic Navigation System) after being technologically integrated with the Columbus™ 3D EP Navigation System (hereinafter referred to as Columbus™ System).
At the symposium site, the operator remotely manipulated the Magnetic Navigation System and the Columbus™ System located in Shanghai MicroPort EP exhibition hall, demonstrated the latest functions after the technological integration, meanwhile invited many participated experts to experience catheter operations in complicated positions on site. After the experience, the participated experts affirmed the new functions of the Magnetic Navigation System and put forward valuable suggestions after understanding its working principles.
As the global leader in the field of Endovascular Interventional Robot, the Magnetic Navigation System of Stereotaxis is featured with easy positioning, stable contact, precise operation, and intelligent automation. So far, over 140,000 procedures have been achieved worldwide with this system. In 2021, MicroPort EP reached a comprehensive strategic partnership with Stereotaxis to actively drive the promotion and registration of the Magnetic Navigation System in China, and to work together to develop a series of cardiac electrophysiological ablation and diagnostic catheters.
As a long-term strategic partner of Stereotaxis on technology and business, MicroPort EP will continue to make improvements in the development of magnetic navigation electrophysiological robot technology in the future, to provide highly innovative and differentiated products for the electrophysiology field in China, to promot the technological advancement and service upgrading of electrophysiological robots, and to provid solutions for more physicians and patients with arrhythmia.